Our results indicate that despite expression of constitutively-active JAK2V617F, the PV phenotype in this mouse model still required THPO signaling and suggest that interfering with the MPL-THPO interaction could have therapeutic value treating the MPN. Here, MPL is linked to myeloproliferative disorder.